Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations(13 sites)
United States
Yale Cancer Center - Yale New Haven Hospital, New Haven, Connecticut The University of Texas M. D. Anderson Cancer Center, Houston, Texas France
Institut Bergonie, Bordeaux Spain
START La Rioja, Hospital Universitario San Pedro, Logroño, La Rioja Hospital Universitari Vall d'Hebron, Barcelona START Barcelona, CIOCC, Hospital Universitario Nou Delfos, Barcelona Hospital Universitario Reina Sofía, Córdoba Hospital 12 de Octubre, Madrid START Madrid-CIOCC, Hospital Universitario HM Sanchinarro, Madrid Hospital Universitario Virgen de la Victoria, Málaga Universitary Hospital Virgen del Rocio, Seville Instituto Valenciano de Oncologia, Valencia